ATOS Atossa Genetics Inc.

-0.0048  -1%
Previous Close 0.47
Open 0.47
Price To book 0.57
Market Cap 1.76M
Shares 3,786,000
Volume 35,871
Short Ratio 0.64
Av. Daily Volume 222,105

SEC filingsSee all SEC filings

  1. 8-K - Current report 17835429
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17835403
  3. DEF 14A - Other definitive proxy statements 17759222
  4. 8-K - Current report 17736139
  5. 424B3 - Prospectus [Rule 424(b)(3)] 17729646

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment to be completed by August 2017.
Cuctal carcinoma in situ(DCIS) - invasive breast cancer

Latest News

  1. Atossa Genetics Completes Enrollment in Topical Arm of Endoxifen Phase 1 Study
  2. Atossa Genetics Announces First Quarter 2017 Financial Results and Provides Company Update
  3. Atossa Genetics Receives Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose Escalation Study
  4. Atossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study
  5. Atossa Genetics Receives Positive Interim Review From Independent Safety Committee in Phase 1 Endoxifen Dose Escalation Study
  6. Atossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study
  7. Atossa Genetics Closes Public Offering
  8. Seattle breast cancer company stock plummets as it seeks funding to continue operations
  9. Atossa Genetics, Inc. Prices $4,000,000 Public Offering
  10. Atossa Genetics Opens Enrollment in Study of Endoxifen
  11. ATOS: Pure Player in the Breast Care Space
  12. Atossa Genetics Provides Update on its Phase 2 Study of Fulvestrant Administered with its Microcatheter
  13. Atossa Genetics to Present at the 9th Annual Biotech Showcase Conference on January 9, 2017
  14. Atossa Genetics Appoints Jack Cuzick, PhD, FRS, FMedSci, FRCP (hon) as Scientific Advisor
  15. Atossa Genetics Announces Reverse Stock Split
  16. Atossa Genetics to Provide Company Update and Discuss Second Quarter Financial Results on Conference Call on Monday, August 15, 2016
  17. Atossa Genetics Settles Litigation With Besins Healthcare
  18. SeeThruEquity Initiates Coverage on Atossa Genetics, Inc. with a Price Target of $1.15
  19. Atossa Genetics Initiates Additional Drug Development Program
  20. Atossa Genetics to Present at 6th Annual LD Micro Invitational Conference on June 7th, 2016